Table 1.
Comparison of the Study Population and Patients Excluded Attributed to Logistical Difficulties or Declined Participation
| Variables | Patients Included Into the SMURF Study N=192 | Patients Excluded Attributed to Logistical Difficulties or Declined Participation N=118 | P Value |
|---|---|---|---|
| Age, mean | 60.5±10.5 | 60.3±11.9 | 0.871 |
| Female sex (%) | 56 (29.2) | 42 (35.3) | 0.259 |
| BMI | 27.9 (IQR 4.2) | 27.4 (IQR 6.5) | 0.984 |
| Paroxysmal AF (%) | 71 (37.4) | 42 (35.3) | 0.764 |
| Hypertension (%) | 80 (42.1) | 59 (49.6) | 0.173 |
| Diabetes mellitus (%) | 15 (7.8) | 12 (10.2) | 0.489 |
| Heart diseasea | 26 (13.5) | 11 (9.2) | 0.24 |
| IHD (%) | 15 (7.8) | 6 (5) | 0.516 |
| SVT (%) | 38 (19.8) | 24 (20.2) | 0.936 |
| Stroke/TIA (%) | 19 (10) | 9 (7.6) | 0.485 |
| Beta‐blocker (%) | 139 (73.2) | 81 (68.1%) | 0.332 |
| AAD (%) | 105 (54.7) | 66 (55.5) | 0.894 |
| ACEi or ARB (%) | 77 (48.5) | 51 (42.9) | 0.632 |
| Statins (%) | 56 (29.5) | 26 (21.8) | 0.155 |
| AF at the ablation lab (%) | 51 (27) | 34 (28.8) | 0.666 |
| Procedural time, min | 186±49.6 | 173±49.8 | 0.025 |
| Fluoroscopy time, minutes | 21 (IQR 13) | 21.5 (IQR 14) | 0.215 |
| Primary successful procedure (%) | 172 (90.5) | 100 (84) | 0.151 |
| Complications (%) | 7 (3.7) | 5 (4.2) | 0.805 |
| Normal LV function (%) | 143 (74.5) | 90 (75.6) | 0.854 |
Normal disturbed data are presented as mean values±SD and possible differences examined with t test, nonparametric data are presented as median values with IQR and tested with Mann–Whitney U test, and categorical data are presented as counts with percent values within brackets and tested with chi‐square test. AAD indicates antiarrhythmic drugs; ACEi, angiotensin‐converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index (kg/m2); EF, ejection fraction; IHD, ischemic heart disease; IQR, interquartile range; SVT, supraventricular tachycardia; TIA, transient ischemic attack.
Patients with dilated, hypertrophic, ischemic, restrictive cardiomyopathy, and perimyocarditis.